Chronic hepatitis C course at elderly and therapeutic approach
Abstract
The aim of review. To discuss features of course of chronic hepatitis C virus infection at elderly, efficacy and safety of antiviral treatment of patients of this age group.
Original positions. In every day clinical practice elderly patients with chronic hepatitis C are extremely rarely considered as candidates for antiviral treatment. Such therapeutic tacticsis is not always justified. At patients in the age of 65 and over chronic hepatitis C has more severe course, than at young patients, with more rapid progression of fibrosis and low level of alanine transaminase. Due to this liver cirrhosis (LC) at elderly patients is more frequent, than at younger subjects. In series of studies it was demonstrated, that elderly age is independent risk factor of development of both LC, and hepatocellular carcinoma. Expediency of prescription of antiviral therapy to elderly patients should be solved individually, taking into account patient’s activity and quality of life. To assess the stage of disease and degree of fibrosis methods, alternative to liver biopsy, are preferable. Before onset of treatment, additional investigation to establish severity of concomitant diseases and risk of their complications should be carried out. One of the basic problems during antiviral therapy is development of ribavirin-induced anemia that is especially dangerous at patients with cardio-vascular diseases. This complication requires careful monitoring of hemoglobin and hematocrit level during the whole period of treatment and, if necessary, decline of drug doses according to established algorithms.
Conclusion. Elderly age is not an absolute contraindication for antiviral treatment. At solving a question of prescription of antiviral therapy for chronic hepatitis C to elderly patients it is necessary to represent clearly the balance of the possible harm and benefits as well as the probable consequences of treatment cancellation.
About the Authors
M. V. Mayevskaya
ГОУ ВПО «1-й Московский государственный медицинский университет им. И.М. Сеченова Росздрава»
Russian Federation
Russian Federation
M. A. Morozova
ГОУ ВПО «1-й Московский государственный медицинский университет им. И.М. Сеченова Росздрава»
Russian Federation
Russian Federation
References
1. Ивашкин В.Т. Болезни печени и желчевыводящих путей: Руководство для врачей. – 2-е изд. – М.: Изд. Дом. «М-Вести», 2005. – 230 с.
2. Ивашкин В.Т., Морозова М.А., Маевская М.В. и др. Факторы риска развития гепатоцеллюлярной карциномы // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 1. – С. 4–16.
3. Ивашкин В.Т., Морозова М.А., Маевская М.В., Федосьина Е.А. Препараты растительного происхождения в лечении гепатита С // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 3. – С. 70– 75.
4. Ben Yehuda A., Globerson A., Krichevsky S. et al. Ageing and mismatch repair system // Mech. Ageing Dev. – 2000. – Vol. 121. – P. 173–179.
5. Cainelli F. Hepatitis C Virus infection in the elderly epidemiology, natural history and management // Drugs Aging. – 2008. – Vol. 25, N 1. – P. 9–18.
6. Castera L., Vergniol J., Foucher J. et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C // Gastroenterology. – 2005. – Vol. 128. – P. 343–350.
7. Degos F., Christidis C., Ganne-Carrie N. et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death // Gut. – 2000. – Vol. 47. – P. 131–136.
8. Foster G. et al. AASLD, October 24–28, 2003. – Boston, MA. Abstract 189.
9. Gish R.G., Arora S., Nelson D. et al. End-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa 2a // Hepatology. – 2004. – Vol. 40, N 4 (suppl. 1). – P. 388A.
10. Horikawa N., Yamazaki T., Izumi N. et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alfa therapy: a prospective study // Gen. Hosp. Psychiatry. – 2003. – Vol. 25. – P. 34–38.
11. Imai Y., Kasahara A., Tanaka H. et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response // J. Gastroenterol. – 2004. – Vol. 39. – P. 1069–1077.
12. Iwasaki Y., Ikeda H., Araki Y. et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C // Hepatology. – 2006. – Vol. 43. – P. 54–63.
13. Krawitt E.L., Ashikaga T., Gordon S.R. et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C // J. Hepatol. – 2005. – Vol. 43. – P. 243–249.
14. McBride B.F., White C.M. Anemia management in heart failure: a thick review of thin data // Pharmacotherapy. – 2004. – Vol. 24, N 6. – P. 757–767.
15. McHutchison J., Manns M., Lon-go D. Definition and management of anemia in patients infected with hepatitis C virus // Liver Int. – 2006. – Vol. 26. – P. 389–398.
16. Minola E., Prati D., Suter F. et al. Age of infection affects the long-term outcome of transfusion-associated chronic hepatitis C // Blood. – 2002. – Vol. 99. – P. 4588–4591.
17. Nomura H., Tanimoto H., Kajiwara E. et al. Factors contributing to ribavirin-induced anemia // J. Gastroenterol. Hepatol. – 2004. – Vol. 19. – P. 1312– 1317.
18. Nudo C.G., Wong P., Hilzenrat N. et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C // Can. J. Gastroenterol. – 2006. – Vol. 20. – P. 589–592.
19. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C // Lancet. – 1997. – Vol. 349. – P. 825–832.
20. Poynard T., McHutchison J., Manns M. et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin // Hepatology. – 2003. – Vol. 38. – P. 481–492.
21. Poynard T., Ratziu V., Charlotte F. et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C infection and alanine aminotransferase levels in the general // J. Hepatol. – 2001. – Vol. 34. – P. 730–739.
22. Rivkin A., Chawla S. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus // Pharmacotherapy. – 2005. – Vol. 25, N 6. – P. 862–875.
23. Roche. Copegus medication guide. – Nutley (NJ): Roche, 2007.
24. Salkowski M.S., Wasserman R., Brooks L. et al. Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C viral infection // Hepatology. – 2004. – Vol. 11. – P. 243– 250.
25. Schering Plough. Rebetol product information. Kenilworth. Schering Plough, 2007 Sep
26. Shiffman M.L., di Bisceglie A.M., Lindsay K.L. et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior therapy // Gastroenterology. – 2004. – Vol. 126. – P. 1015–1023.
27. Shiratori Y., Ito Y., Yokosuka O. et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival // Ann. Intern. Med. – 2005. – Vol. 142. – P. 105–114.
28. Strader D.B., Wright T., Thomas D.L. et al. Diagnosis, management, and treatment of hepatitis C: American Association for the Study of Liver Diseases // Hepatology. – 2004. – Vol. 39. – P. 1147–1171.
29. Takaki S., Tsubota A., Hosaka T. et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa 2b // J. Gastroenterol. – 2004. – Vol. 39. – P. 668–673.
30. Thabut D., Le Calvez S., Thibault V. et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1260–1267.
31. Watson J.P., Brind A.M., Chapman C.E. et al. Hepatitis C virus: epidemiology and genotypes in the north east of England // Gut. – 1996. – Vol. 38. – P. 269–276.
Review
For citations:
Mayevskaya M.V., Morozova M.A. Chronic hepatitis C course at elderly and therapeutic approach. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(1):11-18. (In Russ.)
Views:
73
Email this article 
